Neuphoria Therapeutics (NEUP) Cash & Equivalents (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Cash & Equivalents data on file, last reported at $19.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 13.82% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 13.82% YoY) and the FY2025 annual result came in at $14.2 million, up 12.71% from the prior year.
• Cash & Equivalents eased to $19.4 million in Q1 2026 per NEUP's latest filing, from $22.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $24.0 million in Q2 2022 and bottomed at $4.3 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $12.6 million (2024), against an average of $13.4 million.
• The widest annual swing landed in 2024, when Cash & Equivalents sank 57.22%; it then soared 410.3% in 2025.
• Tracing NEUP's Cash & Equivalents over 5 years: stood at $24.0 million in 2022, then slumped by 57.76% to $10.2 million in 2023, then sank by 57.22% to $4.3 million in 2024, then soared by 410.3% to $22.2 million in 2025, then fell by 12.5% to $19.4 million in 2026.
• Per Business Quant, the three latest NEUP Cash & Equivalents figures stand at $19.4 million (Q1 2026), $22.2 million (Q4 2025), and $13.6 million (Q3 2025).

Peer Comparison